Tag Archives: Juno Therapeutics

Analysts Have Conflicting Sentiments on These Healthcare Companies: Juno Therapeutics (NASDAQ: JUNO), Amag Pharmaceuticals (NASDAQ: AMAG) and Aerie Pharma (NASDAQ: AERI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Juno Therapeutics (NASDAQ: JUNO), Amag Pharmaceuticals (NASDAQ: AMAG) and Aerie Pharma (NASDAQ: AERI). Juno Therapeutics (NASDAQ: JUNO) In a report released yesterday, Chris Shibutani from

Cowen & Co. Believes Juno Therapeutics (NASDAQ: JUNO) Still Has Room to Grow

In a report released yesterday, Chris Shibutani from Cowen & Co. reiterated a Buy rating on Juno Therapeutics (NASDAQ: JUNO), with a price target of $49. The company’s shares closed yesterday at $43.53, close to its 52-week high of $47.03.

Maxim Group Believes Juno Therapeutics (NASDAQ: JUNO) Won’t Stop Here

Maxim Group analyst Jason McCarthy assigned a Buy rating to Juno Therapeutics (NASDAQ: JUNO) today and set a price target of $56. The company’s shares closed on Friday at $43.61, close to its 52-week high of $47.03. McCarthy observed: “The

Juno Therapeutics Gets a Hold Rating from Morgan Stanley

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Juno Therapeutics (NASDAQ: JUNO), with a price target of $43. The company’s shares opened today at $44.70, close to its 52-week high of $47.03. According

Juno Therapeutics Got Some Bad News

Standpoint Research analyst Ronnie Moas downgraded Juno Therapeutics (NASDAQ: JUNO) to Sell today. The company’s shares opened today at $41.12, close to its 52-week high of $44.60. According to TipRanks.com, Moas is a 5-star analyst with an average return of

Wedbush Believes Juno Therapeutics (NASDAQ: JUNO) Won’t Stop Here

Wedbush analyst David Nierengarten upgraded Juno Therapeutics (NASDAQ: JUNO) to Buy today. The company’s shares closed yesterday at $36.48, close to its 52-week high of $37.50. According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 25.2%